Yukinori Okada^1*, Tatsuyuki Abe¹, Mio Shinozaki¹, Shinjiro Sakaino¹, Hiromichi Gomi¹, Yasuo Nakajima¹, Yasuyuki Kojima², Tomoko Uejima², Koichiro Tsugawa²

Show more
¹ Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan.
² Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Japan.
Show less

Abstract: In this study, we evaluate the analgesic effect of strontium-89 (Sr-89) for patients with breast cancer having multiple bone metastases and identify positive predictive factors. We retrospectively evaluated 15 patients who were administered Sr-89 for painful bone metastases from breast cancer at St. Marianna University Hospital between January 2010 and April 2014. For patients receiving multiple doses, only the first dose was evaluated. Pain relief was defined as a decrease in the score of the Numeric Rating Scale (NRS) or requirement of reduced doses of pain medication 1 - 2 months after being on Sr-89 administration. The associations between pain relief owing to Sr-89 and that owing to bone scan index, interval from bone metastasis onset to Sr-89 administration, zoledronate and denosumab treatment history, hormone therapy/aromatase inhibitor history, and chemotherapy history were assessed. A logistic model was used for statistical analysis. Pain relief was observed in 11 (73.3%) of 15 patients. No statistically significant value was observed between pain relief and bone scan index, interval from bone metastasis onset to Sr-89 administration, zoledronate and denosumab treatment history, hormone therapy/aromatase inhibitor history, and chemotherapy. Thus, Sr-89 was effective for 70% of patients with breast cancer bone metastases, although positive predictive factors for pain relief could not be determined.

Keywords: Breast Cancer, 89-Sr, Analgesia

Cite this paper: Okada, Y. , Abe, T. , Shinozaki, M. , Sakaino, S. , Gomi, H. , Nakajima, Y. , Kojima, Y. , Uejima, T. and Tsugawa, K. (2018) Strontium-89 Therapy for Breast Cancer Bone Metastases: Pain Relief Effects and Predictive Factors. Advances in Breast Cancer Research, 7, 250-257. doi: 10.4236/abcr.2018.74016.

References

[1]   Sanuki, N., Ono, A., Komatsu, E., Kamei, N., Akamine, S., Yamazaki, T., Mizunoe, S. and Maeda, T. (2012) Association of Computed Tomography-Detected Pulmonary Interstitial Changes with Severe Radiation Pneumonitis for Patients Treated with Thoracic Radiotherapy. Journal of Radiation Research, 53, 110-116.
https://doi.org/10.1269/jrr.110142

[2]   Nieder, C., Grosu, A.L., Andratschke, N.H. and Molls, N. (2005) Proposal of Human Spinal Cord Reirradiation Dose Based on Collection of Data from 40 Patients. International Journal of Radiation Oncology*Biology*Physics, 61, 851-855.
https://doi.org/10.1016/j.ijrobp.2004.06.016

[3]   Baziotis, N., Yakoumakis, E., Zissimopoulos, A., Geronicola-Trapali, X., Malamitsi, J. and Proukakis, C.H. (1998) Strontium-89 Chloride in the Treatment of Bone Metastases from Breast Cancer. Oncology, 55, 377-381.
https://doi.org/10.1159/000011881

[4]   Fuster, D., Herranz, D., Vidal-Sicart, S., Munoz, M., Conill, C., Mateos, J.J., Martin, F. and Pons, F. (2000) Usefulness of Strontium-89 for Bone Pain Palliation in Metastatic Breast Cancer Patients. Nuclear Medicine Communications, 21, 623-626.
https://doi.org/10.1097/00006231-200007000-00004

[5]   Dafermou, A., Colamussi, P., Giganti, M., Cittanti, C., Bestagno, M. and Piffanelli, A. (2001) A Multicentre Observational Study of Radionuclide Therapy in Patients with Painful Bone Metastases of Prostate Cancer. European Journal of Nuclear Medicine, 28, 788-798.
https://doi.org/10.1007/s002590100533

[6]   Kraeber-Bodéré, F., Campion, L., Rousseau, C., Bourdin, S., Chatal, J.F. and Resche, I. (2000) Treatment of Bone Metastases of Prostate Cancer with Strontium-89 Chloride: Efficacy in Relation to the Degree of Bone Involvement. European Journal of Nuclear Medicine, 27, 1487-1493.
https://doi.org/10.1007/s002590000315

[7]   Windsor, P.M. (2001) Predictors of Response to Strontium-89 (Metastron) in Skeletal Metastases from Prostate Cancer: Report of a Single Centre 10-Year Experience. Clinical Oncology, 13, 219-227.
https://doi.org/10.1053/clon.2001.9257

[8]   Guidelines for the Therapeutic Administration of Strontium 89. Radiaton Safety Program Department of Human Service. Publication No. 95/0386.6.

[9]   Blake, G.M. and Fogelman, I. (2013) Bone: Strontium Ranelate Does Not Have an Anabolic Effect on Bone. Nature Reviews Endocrinology, 9, 696-697.
https://doi.org/10.1038/nrendo.2013.210

[10]   Ackery, D. and Yardley, J. (1993) Radionuclide-Targeted Therapy for the Management of Metastatic Bone Pain. Seminars in Oncology, 20, 27-31.

[11]   McEwan, A.J. (2000) Use of Radionuclides for the Palliation of Bone Metastases. Seminars in Radiation Oncology, 10, 103-114.
https://doi.org/10.1016/S1053-4296(00)80047-8

[12]   Yamada, K., Yoshimura, M. and Kaise, H. (2012) Current Use of Sr 89 Chloride with Zoledronic Acid Is Safe and Effective for Breast Cancer Patients with Painful Bone Metastases. Experimental and Therapeutic Medicine, 3, 226-230.
https://doi.org/10.3892/etm.2011.405